Study of GEC255 in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation

Summary

The overall objective of this Phase 1 study is to evaluate the safety, Pharmacokinetics (PK), and anti-tumor activity of daily oral dosing with GEC255 tablets in subjects with advanced solid tumor with Kirsten Rat Sarcoma (KRAS) p.G12C mutation. To determine the recommended Phase 2 dose (RP2D) based on assessments of multiple dose escalation and expansion in target cohorts.

Timeline

Start

2021-11-04

Primary completion

2024-02-28

Completion

2024-05-30

Drugs

Indications